George Colberg co-founded Kalos Therapeutics with Gregory Witchel in 2005. He has developed the corporate philosophy of Kalos, identified, and worked to explore the primary products, raised seed, grant round, and A round of financing. George recruited and retained the executive team and scientific advisory board while facilitating the clinical development plan. He has investigated new compounds and constructs for potential licensing or acquisition and continues to explore new opportunities for Kalos. His continuing role in the Company will be to create shareholder value, patient benefits, promote corporate governance, assist in establishing corporate regulations and controls, and presiding over executive level functions.
George founded and is the former President and CEO of Primary Care, Inc., one of the first companies to create a solution to the national physician self-referral dilemma. Price Waterhouse and a regional business journal recognized his contributions with their Up & Comer Award in Finance. George has experience in corporate finance and management.
michael kozlowski, od, phd
chief science officer
Michael, our Chief Science Officer, oversees the development of the company's therapeutic compounds and the expansion of the company's therapeutic platform. He has over 25 years of experience in the pharmaceutical and biotechnology industries. Michael has been a private consultant to biotechnology companies, advising them on drug discovery and development matters. Before becoming a consultant, he was the COO at Axiom Biotechnologies and helped engineer its sale to Sequenom. Before Axiom, Michael was the VP of Biology at Telik and was the Chair of the Development Team for one of its clinical candidates and a second development team member. Before working in the biotechnology industry, Michael worked with BMS and Pfizer in their preclinical drug discovery and development functions. Michael's laboratory discovered and advanced into clinical trials a pair of first-in-class drug candidates for mood-disorder at Pfizer and three cardiovascular disease and obesity drug candidates at Bristol Myers Squibb.
He earned a B.S. in Biology from the California Institute of Technology, a Ph.D. in Neuroscience from the University of California at Irvine, and an O.D. from the New England College of Optometry.
greg witchel, mba
co-founder and executive vice president
Greg co-founded Kalos Therapeutics with George Colberg in 2005. Greg identified and and worked to explore the primary products and continues to explore business and financial opportunities for Kalos. He has corporate management, finance, investor, and capital formation responsibilities. Greg had previously been CEO and Director of the US parent, and Managing Director of its UK subsidiary, of a publicly traded diagnostic laboratory products and animal health company.